The Efficacy of Adjuvant FOLFOX6 for Patients With Gastric Cancer after D2 Lymphadenectomy

A Propensity Score-matched Analysis

Zi-Xian Wang, MD, Xu-Long Yang, MD, Ming-Ming He, MD, Feng Wang, MD, Dong-Sheng Zhang, MD, Yu-Hong Li, MD, Zhi-Wei Zhou, MD, You-Qing Zhan, MD, and Rui-Hua Xu, MD

Abstract: Adjuvant 5-fluorouracil, folinic acid, and oxaliplatin (FOLFOX6) are widely used for treating resected gastric cancer in clinics in China, but only few clinical trials have investigated its efficacy. Using propensity score matching, we evaluated the efficacy of adjuvant FOLFOX6 following D2 lymphadenectomy.

Patients who received adjuvant FOLFOX6 following D2 lymphadenectomy (FOLFOX6, n = 113) or D2 lymphadenectomy only (surgery-only, n = 512) between 1998 and 2007 at our center were propensity score-matched; we identified a balanced 1:2 cohort, with 96 patients in the FOLFOX6 group and 192 patients in the surgery-only group. The overall survival (OS) was estimated using the Kaplan–Meier method; factors affecting survival were identified by Cox regression models. A nomogram incorporating independent prognosticators was constructed for predicting the 3-, 5-, and 7-year OS, and bootstrap validation was performed.

The median follow-up was 9.3 years, and the 7-year OS was 52.1% in the FOLFOX6 group and 43.8% in the surgery-only group (P = 0.04), with an adjusted hazard ratio of 0.69 (95% confidence interval = 0.49–0.91). A prognostic nomogram was generated with the identified significant prognosticators (adjuvant FOLFOX6, number of total harvested nodes, the interaction effect between these two variables, tumor size, T and N stage). Internal validation of the nomogram revealed good predictive abilities, with a bootstrap-corrected concordance index of 0.70.

Adjuvant FOLFOX6 following D2 lymphadenectomy is associated with survival benefit in resected gastric cancer. Receiving adjuvant FOLFOX6 can be developed into a nomogram with other independent prognosticators to refine OS prediction and estimation of benefit from adjuvant FOLFOX6 for resected gastric cancer.

(Medicine 95(16):e3214)

Abbreviations: 5-FU = 5-fluorouracil, AJCC/UICC = American Joint Committee on Cancer/International Union Against Cancer, C-index = concordance index, FA = folinic acid, FOLFOX6 = 5-Fluorouracil, folinic acid, and oxaliplatin, LN = lymph node, LV = leucovorin, OS = overall survival, PSM = propensity score matching, THN = total harvested lymph nodes, XELOX = capecitabine plus oxaliplatin.

INTRODUCTION

Although the incidence and mortality rate of gastric cancer have been decreasing for decades, it remains the fifth most common malignancy and the third leading cause of cancer-related death worldwide,1 with especially high incidence in East Asia. Radical resection remains the only possible cure for gastric cancer, especially for patients with early-stage disease.2 However, despite extended lymphadenectomies being performed, the high rate of postsurgical recurrence leads to dismal prognoses for patients with locally advanced tumors, suggesting the presence of micrometastatic disease at surgery.3,4 Based on these observations, it was hypothesized that adjuvant chemotherapy could improve outcomes in resected locally advanced gastric cancer,5 and two milestone meta-analyses by the GASTRIC Group and the Cochrane Collaboration confirmed this hypothesis, both demonstrating 15% to 18% reduced risk of death by adjuvant chemotherapy.6,7

However, the best treatment option in the adjuvant setting remains inconclusive. Generally, surgery followed by 5-fluorouracil (5-FU)-based chemoradiotherapy is the standard of care for patients with resected gastric cancer in the United States, which is primarily based on the results of the Intergroup 116 trial, in which only 10% of patients underwent D2 lymphadenectomy.8 For patients who have undergone D2 lymphadenectomy, the use of adjuvant chemotherapy is mainly supported by the ACTS-GC trial and the CLASSIC trial, which used adjuvant S-1 and capecitabine plus oxaliplatin (XELOX), respectively.9,10 In addition, several trials failed to demonstrate the benefit of more intense regimens such as sequential polychemotherapy.11,12

In clinics in China, adjuvant 5-FU, folinic acid (FA), and oxaliplatin (FOLFOX6) were widely used during the period in which standard protocols for adjuvant therapy were lacking.13,14 However, only one small prospective, randomized controlled trial investigating the efficacy of adjuvant FOLFOX (FOLFOX4) in patients with D2-resected gastric cancer was published.15

In the present study, we retrospectively investigated the efficacy of adjuvant FOLFOX6 in patients after D2 lymphadenectomy. Propensity score matching (PSM) was used to adjust for treatment selection bias, and a nomogram was generated to refine the prediction of prognosis and to evaluate the potential benefit from adjuvant FOLFOX6 in these patients.

METHODS

Ethics Statement

All of the patients provided written informed consent for the storage and use of their information in the hospital database. Study approval was obtained from the independent ethics

Editor: Garrett Chi-lai Ho.
Received: October 22, 2015; revised: January 11, 2016; accepted: March 8, 2016.
From the Department of Medical Oncology (Z-XW, M-MH, FW, D-SZ, Y-HL, R-HX), Faculty of Medical Sciences, (Z-XW, X-LY); and Department of Gastric and Pancreatic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China (Z-WZ, Y-QZ). Correspondence: Rui-Hua Xu, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China (e-mail: xurh@sysucc.org.cn).
Z-XW, X-LY, and M-MH contributed equally to this study.
The authors have no conflicts of interest to disclose.
Supplemental Digital Content is available for this article.
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
ISSN: 0025-7974
DOI: 10.1097/MD.0000000000003214

Medicine • Volume 95, Number 16, April 2016 www.md-journal.com | 1
committees at the Sun Yat-sen University Cancer Center. The study was undertaken in accordance with the ethical standards of the World Medical Association Declaration of Helsinki.

**Patient Selection**

Between October 1998 and July 2007, we identified 796 patients who had been diagnosed with gastric cancer and undergone D2 lymphadenectomy at the Sun Yat-sen University Cancer Center. Patients included in the study met the following criteria: (1) aged 20 to 75 years; (2) histologically confirmed stage IB–IIIC gastric adenocarcinoma; (3) underwent histologically confirmed R0 resection, with or without adjuvant FOLFOX4/6; (4) availability of complete clinicopathologic and follow-up data. The exclusion criteria were: (1) death within 90 days of surgery; (2) age >75 years or <20 years; (3) presence of residual macroscopic or microscopic tumor, distant metastasis, or concurrent malignancies in other organs; (4) received neoadjuvant chemoradiotherapy, adjuvant radiotherapy, or adjuvant chemotherapy regimens other than FOLFOX4/6. Eventually, a total of 625 patients were identified as the study cohort: 113 received adjuvant FOLFOX (all received FOLFOX6) and 512 underwent surgery alone.

The clinical decision to administer postoperative chemotherapy was based on the patient’s disease stage, general health, and preference. All of the patients provided informed consent before receiving the adjuvant FOLFOX6. The FOLFOX6 regimen consisted of 2-week cycles of intravenous 100 mg/m² oxaliplatin and 400 mg/m² FA (or 200 mg/m² leucovorin [LV]) over 2 h on day 1 of each cycle, plus 400 mg/m² bolus 5-FU with 2400 mg/m² infusional 5-FU in 46 h for each cycle. The median duration of chemotherapy was six cycles.

**Follow-up**

Following treatment, patients were monitored every 3 months for the first 2 years, and then every 6 months thereafter.

**Statistical Analysis**

The clinicopathologic characteristics of the cohort are described, and the differences in these characteristics between the FOLFOX6 group and surgery-only group were compared. Categorized variables were compared using the chi-square test; continuous variables were compared using the Mann–Whitney U test. Logistic regression analysis was used to identify confounders between the treatment groups. Propensity scores were calculated based on the identified confounders and other important factors such as tumor stage, and then each patient was assigned a score. Using 0.1-caliper width, 1:2 matching was performed between patients in the FOLFOX6 group and surgery-only group based on the propensity scores. This allowed clinical outcomes between the treatment groups to be compared without adjusting for confounders.

Overall survival (OS) was calculated from the date of surgery until final follow-up or death from any cause. The Kaplan–Meier method with log-rank testing was used to assess the unadjusted survival benefit from adjuvant FOLFOX6; multivariate Cox proportional hazards regression was used to assess the survival benefit from adjuvant FOLFOX6 after adjusting for identified prognosticators and to perform interaction tests between treatment and other clinical features. The final logistic and Cox model selection was performed by stepwise forward selection: variables were added using forward selection according to a selection entry criterion of $P < 0.05$ and removed using backward elimination according to a selection stay criterion of $P < 0.05$. A nomogram for predicting individual survival was constructed based on the final Cox model. The comparative discriminative power of the nomogram and the seventh American Joint Committee on Cancer/International Union Against Cancer (AJCC/UICC) staging system was assessed using the concordance index (C-index): a higher C-index indicates more accurate prediction of prognosis. Nomogram calibration was assessed by reviewing the plot of nomogram-predicted survival probabilities versus the Kaplan–Meier-estimated probabilities. Bootstraps with 1000 resamplings were used to quantify any model overfit and to calculate the Kaplan–Meier estimates. All tests were two-sided and a $P$-value of <0.05 was considered statistically significant. Analysis was performed using SPSS version 19.0 (SPSS, Chicago, IL) and R version 3.1.2 (http://www.r-project.org/) statistical packages.

**RESULTS**

**Overall Patient Characteristics**

Table 1 summarizes the patient characteristics before and after PSM. Before PSM, there were significant differences in patient age, tumor location, pathologic T/N stage, and the number of total harvested lymph nodes (THN). After PSM, the confounders identified by multivariate logistic regression (age, tumor location, and T stage) and all of the other clinicopathologic factors were balanced between the treatment arms. The 1:2 propensity score–matched cohort consisted of 288 patients (96 received FOLFOX) with stage IB–IIIC gastric cancer. One hundred and ten patients (38.2%) were aged >60 years, and 129 patients (44.8%) had tumors at the distal third of the stomach. The majority of patients (233, 80.9%) had T4 lesions, and 203 patients (70.5%) had lymph node (LN) metastasis. One hundred and ninety-seven patients (68.4%) had >15 THN. The median follow-up time for the post-PSM cohort was 9.3 years (IQR, 6.2–10.2 years); specifically, 9.7 years for the FOLFOX6 group and 8.3 years for the surgery-only group. During the follow-up, 47 patients (49%) in the FOLFOX6 group and 104 patients (54%) in the surgery-only group died.

**Survival Analysis**

Figure 1A depicts the OS curves for the post-PSM cohort according to treatment arm. The 3-, 5-, and 7-year OS rates were 70.9%, 56.7%, and 52.1%, respectively, in the FOLFOX6 group versus 56.0%, 45.8%, and 43.8%, respectively, in the surgery-only group ($P = 0.04$). After adjusting for tumor size, T stage, N stage, and THN, the hazard ratio (HR) for the FOLFOX6 arm as compared with the control was 0.69 (95% confidence interval [95% CI] = 0.49–0.98, $P = 0.04$), indicating that FOLFOX6 reduced the risk of death by 31% (Table 2).

In subgroup analyses, we observed no significant interaction between treatment and any subgroup for OS, except for THN (Supplementary Table 1, http://links.lww.com/MD/A876). Patients with ≤15 THN apparently benefited more from adjuvant FOLFOX6 as compared with those with >15 THN: the 3-, 5-, and 7-year OS rates of patients with ≤15 THN were 72.4%, 65.2%, and 61.1%, respectively, in the FOLFOX6 group versus 47.9%, 34.9%, and 32.9%, respectively, in the surgery-only group ($P = 0.02$, Figure 1B), whereas that for patients with >15 THN was 67.7%, 53.6%, and 48.6%, respectively, in the FOLFOX6 group and 59.7%, 53.6%, and 48.9%, respectively, in the surgery-only group ($P = 0.91$, Figure 1C), and the interaction was significant ($P = 0.04$, Table 3). Further investigations showed that the distribution of clinical features...
between the treatment groups remained well balanced when stratified by \( \leq 15 \) or \( > 15 \) THN.

### Development of Predictive Nomogram

A nomogram for predicting the 3-, 5-, and 7-year OS was generated using the multivariate analysis results (Figure 2). The independent prognosticators identified in the multivariate analysis, including tumor size, T stage, N stage, and adjuvant FOLFOX6, were incorporated into the nomogram. Moreover, because the effect size of FOLFOX6 differed according to THN, the interaction indicating the magnitude of this difference was included in the nomogram. Grouping the patients evenly into three subgroups according to the tertiles of the nomogram-calculated total scores revealed that each group represented a significantly distinct prognosis (Figure 3A).

The nomogram demonstrated good discrimination, with an unadjusted C-index of 0.71 and a 1000-sample bootstrap-corrected C-index of 0.70, which showed minimal evidence of model overfit. The nomogram had more discriminatory power than the seventh AJCC/UICC staging (unadjusted C-index, 0.67; bootstrap-corrected C-index, 0.66). Calibration plots indicated excellent predictive accuracy for the 3-, 5-, and 7-year OS, with <5% difference between the predicted and actual probabilities in each tertile (Figure 3B–D). These results all show that the nomogram performed favorably in predicting OS.

### DISCUSSION

In this study, adjuvant FOLFOX6 after D2 lymphadenectomy significantly improved the short-term and long-term survival of patients with gastric cancer as compared with surgery only, reducing the risk of death by 31%. Subset analysis suggested that adjuvant FOLFOX6 was more beneficial to patients with \( \leq 15 \) THN than to those with \( > 15 \) THN. To assist clinical management, the results were developed into a nomogram to predict the 3-, 5-, and 7-year OS of patients after D2 lymphadenectomy. We verified that the nomogram has good discrimination and calibration.

In addition to estimating survival probabilities, our nomogram also provides individual estimates of potential benefit from adjuvant FOLFOX6, which is helpful for management decisions. For example, a patient with stage pT4N1 (36 + 62 = 98 points) and 6-cm diameter (31 points) gastric cancer who receives adjuvant FOLFOX following surgery with a total 10 LNs harvested (0 points) would have a total score of 129 points, yielding an estimated 7-year OS of 38%. If the same patient received surgery alone, they would have a total 192

### TABLE 1. Characteristics of the Patient Cohort Before and After PSM

| Variable                  | Before PSM | After PSM | P value | Before PSM | After PSM | P value |
|---------------------------|------------|-----------|---------|------------|-----------|---------|
| Age                       | 0.01       | 0.86      |         | 0.01       | 0.86      |         |
| ≤60                       | 70 (61.9%) | 221 (43.2%) | <0.01  | 60 (62.5%) | 118 (61.5%) | 0.86    |
| >60                       | 43 (38.1%) | 291 (56.8%) |        | 36 (37.5%) | 74 (38.5%)  | 0.42    |
| Gender                    | 0.09       | 0.42      |         | 0.09       | 0.42      |         |
| Men                       | 72 (63.7%) | 367 (71.7%) | <0.01  | 69 (71.9%) | 129 (67.2%) | 0.11    |
| Women                     | 41 (36.3%) | 145 (28.3%) |        | 27 (28.1%) | 63 (32.8%)  | 0.80    |
| Tumor location            |            |           | 0.75    |            |           |         |
| Antrum                    |             |           | 0.29    |             |           |         |
| Corpus                    |             |           | 0.75    |             |           |         |
| Fundus                    |             |           | 0.29    |             |           |         |
| ≤5 cm                     | 67 (62.6%) | 325 (64.2%) |         | 62 (64.6%) | 127 (66.1%) | 0.74    |
| >5 cm                     | 40 (37.4%) | 181 (35.8%) |         | 34 (35.4%) | 65 (33.9%)  |         |
| Lauren classification     |             |           |         |             |           |         |
| Diffuse                   | 0.29       | 0.74      |         | 0.29       | 0.74      |         |
| Intestinal                |             |           |         |             |           |         |
| Mixed                     |             |           |         |             |           |         |
| T stage                   | 0.01       | 0.46      |         | 0.01       | 0.75      |         |
| T1–3                      | 17 (15.0%) | 153 (29.9%) | <0.01  | 16 (16.7%) | 39 (20.3%)  | 0.93    |
| T4                        | 96 (85.0%) | 359 (70.1%) |        | 80 (83.3%) | 153 (79.7%) |         |
| N stage                   | 0.01       | 0.75      |         | 0.01       | 0.75      |         |
| N0                        | 33 (29.2%) | 194 (37.9%) |         | 30 (31.3%) | 55 (28.6%)  |         |
| N1–2                      | 38 (33.6%) | 197 (38.5%) |         | 36 (37.5%) | 81 (42.2%)  |         |
| N3                        | 42 (37.2%) | 121 (23.6%) |         | 30 (31.3%) | 56 (29.2%)  |         |
| THN                       | <0.01      | 0.93      |         | <0.01      | 0.93      |         |
| ≤15                       | 31 (28.7%) | 246 (55.7%) |         | 30 (31.3%) | 61 (31.8%)  |         |
| >15                       | 77 (71.3%) | 196 (44.3%) |         | 66 (68.8%) | 131 (68.2%) |         |

FOLFOX6 = 5-fluorouracil, folinic acid, and oxaliplatin; PSM = propensity score matching; THN = total harvested lymph nodes.
points, and the estimated 7-year OS would be only 10%, suggesting considerable benefit from adjuvant FOLFOX6 for this patient. In contrast, a patient with serosa-positive (36 points), node-negative (0 points), and 3-cm diameter (0 point) disease who receives adjuvant FOLFOX6 after D2 lymphadenectomy with a total 20 LNs harvested (10 points) would have a total 46 points and a corresponding 7-year OS of 74%. If this patient did not receive adjuvant FOLFOX6, the estimated 7-year OS would be 71%, suggesting minimal benefit from FOLFOX6 for this patient. Therefore, FOLFOX6 may be avoided when selecting an adjuvant chemotherapy regimen for this patient.

Several previous studies have failed to demonstrate the significant benefit of adjuvant chemotherapy for patients after D2 lymphadenectomy.21–23 Relatively good survival (range: 48%–86%) in the surgery-only groups was a common feature in these studies, which is mainly attributed to more adequate LN resection in these patients. Therefore, it was hypothesized that patients with more complete LN resection may derive less benefit from adjuvant therapy.24 Consistent with our results, a small, prospective, randomized controlled trial also reported that adjuvant FOLFOX (FOLFOX4) after D2 lymphadenectomy significantly improved 3-year survival outcomes for resected gastric cancer (median THN = 19) as compared with adjuvant 5-FU/LV.15 However, it was unclear whether the favorable outcomes in both treatment arms were because of D2 resection or adjuvant chemotherapy, and further exploratory analysis was impeded because of the small sample size.15

The CLASSIC trial is one of the landmark studies that confirmed the efficacy of adjuvant therapy in patients after D2 lymphadenectomy.10 Significantly improved 5-year disease-free survival and 5-year OS was achieved with 6 months of adjuvant XELOX. The effect size of adjuvant chemotherapy in

| Variable                  | Number (%) | HR | 95% CI      | P value |
|---------------------------|------------|----|-------------|---------|
| Tumor size                |            |    |             |         |
| ≤5 cm                     | 189 (65.6) | 1  |             |         |
| >5 cm                     | 99 (34.4)  | 1.51 | (1.08–2.11) |         |
| T stage                   |            |    |             |         |
| T1–T3                     | 55 (19.1)  | 1  |             |         |
| T4                        | 233 (80.9) | 1.75 | (1.02–2.98) |         |
| N stage                   |            |    |             |         |
| N0                        | 85 (29.5)  | 1  |             | <0.01   |
| N1                        | 54 (18.8)  | 1.03 | (0.58–1.82) |         |
| N2                        | 64 (21.9)  | 2.36 | (1.44–3.86) |         |
| N3                        | 86 (29.9)  | 3.98 | (2.52–6.29) |         |
| THN                       |            |    |             |         |
| ≤15                       | 91 (31.6)  | 1  |             |         |
| >15                       | 197 (68.4) | 0.66 | (0.46–0.93) |         |
| Receipt of FOLFOX6        |            |    |             |         |
| No                        | 192 (66.7) | 1  |             | 0.04    |
| Yes                       | 96 (33.3)  | 0.69 | (0.49–0.98) |         |

95% CI = 95% confidence interval; FOLFOX6 = 5-fluorouracil, folinic acid, and oxaliplatin; HR = hazard ratio; THN = total harvested lymph nodes.
our study was similar as compared with the CLASSIC trial (adjusted HR = 0.69 vs. 0.64), although the 5-year OS was better in both the treatment and control arms of the CLASSIC trial than in our study (treatment arm: 78% vs. 57%; control arm: 69% vs. 46%). One possible explanation is the different distribution of the clinicopathologic features between the two studies: the average THN was much higher in the CLASSIC trial than in our study (45.0 vs. 20.2), and the proportion of patients with T4 disease was much greater in our study than in the CLASSIC trial (81% vs. 44%). In addition, as a randomized

**TABLE 3. Multivariate Model Incorporating the Interaction Effect Between Adjuvant FOLFOX6 and THN for Predicting OS**

| Variable               | Number (%) | HR    | 95% CI         | P value |
|------------------------|------------|-------|----------------|---------|
| **Tumor size**         |            |       |                |         |
| ≤5 cm                  | 189 (65.6) | 1     |                | 0.01    |
| >5 cm                  | 99 (34.4)  | 1.55  | (1.11–2.17)    | <0.05   |
| **T stage**            |            |       |                |         |
| T1–T3                  | 55 (19.1)  | 1     |                | <0.01   |
| T4                     | 233 (80.9) | 1.72  | (1.00–2.94)    |         |
| **N stage**            |            |       |                |         |
| N0                     | 85 (29.5)  | 1     |                | <0.01   |
| N1                     | 54 (18.8)  | 1.03  | (0.58–1.82)    |         |
| N2                     | 64 (21.9)  | 2.38  | (1.46–3.90)    |         |
| N3                     | 86 (29.9)  | 4.07  | (2.57–6.44)    |         |
| THN*                   |            |       |                | 0.01    |
| Receipt of FOLFOX6*    |            |       |                | 0.01    |
| Interaction effect* (THN and FOLFOX6) | – | – | 0.04 |
| Receipt of FOLFOX6 by THN |            |       |                |         |
| THN ≤ 15               |            |       |                | 0.02    |
| No                     | 61 (21.2)  | 1     |                |         |
| Yes                    | 30 (10.4)  | 0.46  | (0.25–0.87)    |         |
| THN > 15               |            |       |                | 0.91    |
| No                     | 131 (45.5) | 1     |                |         |
| Yes                    | 66 (22.9)  | 0.98  | (0.64–1.48)    |         |

*Hazard ratios for THN and adjuvant FOLFOX6 are not shown because there was significant interaction between the two variables, which indicates that the HR for adjuvant FOLFOX6 differs according to THN. Accordingly, the HRs for adjuvant FOLFOX6 according to THN subgroups are presented.

95% CI = 95% confidence interval; FOLFOX6 = 5-fluorouracil, folinic acid, and oxaliplatin; HR = hazard ratio; THN = total harvested lymph nodes.

**FIGURE 2.** Prognostic nomogram for predicting 3-, 5-, and 7-year OS in patients with resected gastric cancer. For the factor “Adjuvant FOLFOX6 (Yes/No),” the points assigned should be chosen based on whether the patient had ≤15 or >15 THN. FOLFOX6 = 5-fluorouracil, folinic acid, and oxaliplatin; THN = total harvested lymph nodes.
controlled trial, the CLASSIC study had strict inclusion criteria, and the selected patients were in relatively good health. Therefore, the comparison of treatment efficacy between our study and the CLASSIC trial should be viewed with caution.

As it is unclear whether adjuvant XELOX outperforms adjuvant FOLFOX6, two retrospective Chinese studies compared the efficacy of FOLFOX6 with XELOX in the adjuvant setting after D2 lymphadenectomy. Through PSM, Wu et al observed no significant difference in efficacy between adjuvant XELOX and FOLFOX6 and no significant difference of incidence of grade 3/4 adverse effects except for more common hand–foot syndrome in the XELOX arm. The study by Chen et al from our cancer center also derived a similar conclusion for patients who had undergone total gastrectomy: who are usually diagnosed with late-stage disease and less tolerance to digestive tract toxicity. Despite the higher rate of treatment completion in the XELOX group, the 1-, 3-, and 5-year OS did not differ significantly between the treatment arms, and the incidence of grade 3/4 adverse effects was not significantly different between the treatment arms, except hand–foot syndrome was more common in the XELOX group. In addition, the M66001 trial found that the efficacy of adjuvant single-agent capecitabine and 5-FU/FA was similar in patients with resected colon cancer. All these findings suggest that FOLFOX may be an equivalent and well-tolerated alternative regimen to XELOX in the adjuvant setting for patients with gastric cancer. However, in view of the small sample size of patients receiving FOLFOX in the studies by Wu et al and Chen et al, further research on this issue is warranted.

The present study has some limitations. First, it is based on retrospective data, and there may have been treatment selection bias. Although PSM and multivariate regression were used to reduce this bias, some unaccounted confounders could still have existed between the treatment groups because of the retrospective nature and small sample size of this study. Therefore, a randomized trial or larger sample size is needed to confirm conclusions of this study. Second, we did not collect the data on treatment compliance and adverse effects for the FOLFOX6 group. However, FOLFOX4/6 has shown good tolerability in the adjuvant setting. In addition, the long follow-up period (median: 9.3 years) in our study could help us gain insight into the combined effect of benefit and toxicity from FOLFOX6 on long-term survival. Third, as with any predictive model, the point estimates in our nomogram might have an increased uncertainty range when applied to patients who do not have the clinicopathologic features typical of those used to generate the present nomogram. Therefore, external validation is needed. However, the 1000-sample bootstrap-corrected C-index of 0.70 for our nomogram suggests sufficient predictive accuracy and is comparable to the C-indices reported in previous nomograms (range: 0.68–0.80).

In conclusion, we demonstrate that adjuvant FOLFOX6 therapy is associated with short-term and long-term survival benefit for patients with gastric cancer after D2 lymphadenectomy, especially for those with ≤15 LNs harvested. The results were developed into a nomogram to refine the prediction of OS for patients with resected gastric cancer. The nomogram was verified for discrimination and calibration, and internally
validated by bootstrap resampling. It may be a useful tool in prognosis and treatment programming if externally validated.

ACKNOWLEDGMENTS

We gratefully thank the staff members in the Department of Medical Oncology at Sun Yat-sen University Cancer Center for their suggestion and assistance.

REFERENCES

1. Ferlay J, Ervik M, Dikshit R, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon. France: International Agency for Research on Cancer; 2013: Available at: http://globocan.iarc.fr.

2. Dikken JL, van de Velde CJ, Coit DG, et al. Treatment of resectable gastric cancer. Ther Adv Gastroenterol. 2012;5:49–69.

3. Rivera F, Vega-Villegas ME, Lopez-Brea MF. Chemotherapy of advanced gastric cancer. Cancer Treat Rev. 2007;33:315–324.

4. Siewert JR, Tomasello G, Bregni G, et al. Adjuvant chemotherapy for gastric cancer: current evidence and future challenges. World J Gastroenterol. 2014;20:4516–4525.

5. Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy following curative resection of gastric adenocarcinoma: a meta-analysis. JAMA. 2010;303:1729–1739.

6. Diaz-Nieto R, O’Rourke R, Winslet M. Post-surgical chemotherapy versus surgery alone for resectable gastric cancer. Cochrane Database Syst Rev. 2013;9:Cd008415.

7. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–730.

8. Sasaki M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–4393.

9. Noh SH, Park SR, Yang H-K, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASICC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1389–1396.

10. Tsujinaka A, Yoshida K, Kobayashi M, et al. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. Lancet Oncol. 2014;15:886–893.

11. Dikken JL, Baser RE, Gonen M, et al. Conditional probability of survival nomogram for 1-, 2-, and 3-year survivors after an R0 resection for gastric cancer. Ann Surg Oncol. 2013;20:1623–1630.

12. Bajetta E, Buzzoni R, Mariani L, et al. Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol. 2002;13:299–307.

13. Wu Y, Wei ZW, He YL, et al. Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer. World J Gastroenterol. 2013;19:3309–3315.

14. Chen S, Feng X, Li Y, et al. Efficacy and safety of XELOX and FOLFOX6 adjuvant chemotherapy following radical total gastrectomy. Oncol Lett. 2012;3:781–786.

15. Zhang XL, Shi HJ, Cui SZ, et al. Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma. Eur J Surg Oncol. 2011;37:466–472.

16. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999;150:327–333.

17. Dehejia RH, Wahba S. Propensity score-matching methods for nonexperimental causal studies. Rev Econ Stat. 2002;84:151–161.

18. Harrell FE Jr, Califf RM, Pryor DB, et al. Evaluating the yield of medical tests. JAMA. 1982;247:2543–2546.

19. Hirabayashi S, Kosugi S, Isobe Y, et al. Development and external validation of a nomogram for overall survival after curative resection in serosa-negative, locally advanced gastric cancer. Ann Oncol. 2014;25:1179–1184.

20. Iasonos A, Schrag D, Raj GV, et al. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26:1364–1370.

21. Bajetta E, Buzzoni R, Mariani L, et al. Adjuvant chemotherapy in gastric cancer: current evidence and future challenges. Ann Surg Oncol. 2008;15:2282–2287.

22. Nashimoto A, Nakajima T, Furukawa H, et al. Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer. Cancer. 2006;92:696–706.

23. Miyashiro I, Furukawa H, Sasaki M, et al. Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral Fluorouracil (UFT) in serosa-positive gastric cancer versus curative resection alone: final results of the Japan Clinical Oncology Group trial JCOG9206-2. Gastric Cancer. 2011;14:212–218.

24. Di Costanzo F, Gasperoni S, Manzione L, et al. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst. 2008;100:388–398.

25. Zhan YQ, Li W, Sun XW, et al. Long-term results of surgical treatment of stomach cancer: clinical experience of forty years from Sun Yat-sen University Cancer Center. Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]. 2005;43:1109–1113.

26. Twelves C, Wong A, Nowacki MP, et al. Capicitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696–2704.

27. Bowe O, Ychou M, Burtin P, et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol. 2005;16:1488–1497.

28. Kattan MW, Karpeh MS, Mazumdar M, et al. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol. 2003;21:3647–3650.

29. Han DS, Suh YS, Kong SH, et al. Nomogram predicting long-term survival after d2 gastrectomy for gastric cancer. J Clin Oncol. 2012;30:3834–3840.

30. Kim Y, Spolverato G, Ejaz A, et al. A nomogram to predict overall survival and disease-free survival after curative resection of gastric adenocarcinoma. Ann Surg Oncol. 2015;22:1828–1835.

31. Song KY, Park YG, Jeon HM, et al. A nomogram for predicting individual survival of patients with gastric cancer who underwent radical surgery with extended lymph node dissection. Gastric Cancer. 2014;17:287–293.

32. Lai JF, Kim S, Kim K, et al. Prediction of recurrence of early gastric cancer after curative resection. J Clin Oncol. 2009;27:1896–1902.

33. Dikken JL, Baser RE, Gonen M, et al. Conditional probability of survival nomogram for 1-, 2-, and 3-year survivors after an R0 resection for gastric cancer. Ann Surg Oncol. 2013;20:1623–1630.